Windtree Therapeutics Inc... (WINT)
NASDAQ: WINT
· Real-Time Price · USD
0.90
-0.12 (-11.76%)
At close: May 06, 2025, 3:59 PM
0.87
-3.19%
After-hours: May 06, 2025, 05:42 PM EDT
-11.76% (1D)
| Bid | 0.87 |
| Market Cap | 3.28M |
| Revenue (ttm) | 45K |
| Net Income (ttm) | -5.49M |
| EPS (ttm) | -5217.5 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.91 |
| Volume | 1,524,634 |
| Avg. Volume (20D) | 2,951,402 |
| Open | 0.95 |
| Previous Close | 1.02 |
| Day's Range | 0.83 - 0.99 |
| 52-Week Range | 0.83 - 737.50 |
| Beta | 0.91 |
About WINT
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF,...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 7, 1995
Employees 14
Stock Exchange NASDAQ
Ticker Symbol WINT
Website https://windtreetx.com
Analyst Forecast
According to 1 analyst ratings, the average rating for WINT stock is "Hold." The 12-month stock price forecast is $350, which is an increase of 38845.14% from the latest price.
Stock Forecasts1 month ago
+18.92%
Windtree Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
1 month ago
+28.99%
Windtree shares are trading higher after the company entered a license and supply agreement to become a sourcing partner for Evofem Biosciences for Evofem's PHEXXI.
